![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1741463
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå : °Ë»ç À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Frasier Syndrome Market, By Test Type (Genetic Testing, Ultrasound Testing, Others), By End User (Hospitals, Diagnostic Centers, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) |
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀº 2025³â 1¾ï 5,580¸¸ ´Þ·¯, 2032³â¿¡´Â 2¾ï 2,070¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 5.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í¼ ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024 | 2025³â ½ÃÀå ±Ô¸ð | 1¾ï 5,580¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR | 5.10% | 2032³â °¡Ä¡ ¿¹Ãø | 2¾ï 2,070¸¸ ´Þ·¯ |
ÇÁ·¹ÀÌÀú ÁõÈıº(FS)Àº ½ÅÀå°ú ¼º ¹ß´Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Èñ±ÍÇÑ À¯Àü ÁúȯÀÔ´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº ¸»±â ½ÅºÎÀüÀ¸·Î ÁøÇàµÉ ¼ö ÀÖ´Â ½ÅÀå Áúȯ°ú ¿©¼ºÀÇ ¿ù°æ Áֱ⠺ÎÁ·À¸·Î À̾îÁö´Â ¼º¼± Çü¼º ÀÌ»óÀÌ Æ¯Â¡ÀÔ´Ï´Ù.
1964³â ÇÁ¶ó´õ ¹Ú»ç´Â ÇÁ·¹ÀÌÀú ÁõÈıºÀ̶ó´Â ¿ë¾î¸¦ ¸¸µé¾î³Â½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº 11¹ø ¿°»öü ´Ü¿Ï¿¡ ÀÖ´Â WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ À¯ÀüÀÚ´Â ¹è¾Æ ¹ß»ý±âÀÇ ½ÅÀå°ú »ý½Ä¼±ÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ´Â Á¤»óÀûÀÎ ¼¼Æ÷ °úÁ¤À» ÆÄ±«ÇÏ¿© ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Æ¯Â¡ÀûÀΠƯ¡À» °¡Á®¿É´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ ¹ßº´·üÀº Ãâ»ý¾Æ 10¸¸ ¸í´ç 1¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÁÖ·Î ¿©¼º¿¡°Ô ¹ßº´ÇÏÁö¸¸ µå¹°°Ô ³²¼º¿¡°Ôµµ ¹ßº´ÇÑ »ç·Ê°¡ º¸°íµÇ°í ÀÖ½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´ÜÀº ÀÓ»óÀû Ư¡, À¯ÀüÀÚ °Ë»ç, ½ÅÀå Á¶Á÷ÀÇ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¿¡ ±Ù°ÅÇÏ¿© ÀÌ·ç¾îÁý´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÷´Ü Áø´Ü ±â¼úÀÇ ¹ß´Þ·Î ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´ÜÀ²ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, À¯ÀüÀÚ °Ë»ç ¹× ½ºÅ©¸®´×¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
µÑ°, ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ À¯º´·ü Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ½ÅÀå ´ëü ¿ä¹ý°ú Àå±âÀûÀÎ °ü¸® Àü·«ÀÇ Çʿ伺Àº Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
±×·¯³ª ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåµµ ÀÏÁ¤ÇÑ ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ÀϹÝÀÎÀÇ ÀνÄÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ Áø´ÜÀÌ ´Ê¾îÁö°Å³ª Ä¡·á°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ °Ë»ç ¹× Àü¹® Ä¡·á¿¡ ¼Ò¿äµÇ´Â °í°¡ÀÇ ºñ¿ëÀº ȯÀÚ¿Í ±× °¡Á·¿¡°Ô Å« ºÎ´ãÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù.
ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå¿¡´Â ¸î °¡Áö ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·á¿Í ¸ÂÃã ÀÇ·áÀÇ °³¹ß·Î ÇÁ·¹ÀÌÀú ÁõÈıº ȯÀÚÀÇ ¿¹Èİ¡ °³¼±µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ, ¿¬±¸±â°ü, Á¦¾àȸ»ç, Áö¿ø´ÜüÀÇ Çù·ÂÀ¸·Î ´õ ³ªÀº Áø´Ü µµ±¸¿Í Ä¡·á¹ý ¿¬±¸¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
Frasier Syndrome Market is estimated to be valued at USD 155.8 Mn in 2025 and is expected to reach USD 220.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 155.8 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 5.10% | 2032 Value Projection: | USD 220.7 Mn |
Frasier syndrome (FS) is a rare genetic disorder that affects the kidneys and sexual development. It is characterized by the presence of kidney disease, which can progress to end-stage renal disease, and the development of gonadal dysgenesis, leading to the absence of menstrual cycles in females.
Dr. Prader in 1964 coined the term Frasier syndrome. It is caused by mutations in the WT1 gene located on the short arm of chromosome 11. This gene plays a crucial role in the development of the kidneys and gonads during embryogenesis. Mutations in the WT1 gene disrupt normal cellular processes, leading to the characteristic features of Frasier syndrome.
The incidence of Frasier syndrome is estimated to be around 1 in 100,000 live births. It predominantly affects females, although rare cases have been reported in males as well. The diagnosis of Frasier syndrome is based on clinical features, genetic testing, and histopathological examination of kidney tissue.
The market for Frasier syndrome is driven by several factors. Firstly, rising awareness about genetic disorders and the availability of advanced diagnostic techniques have led to an increased diagnosis rate of Frasier syndrome. This has resulted in a growing demand for genetic tests and screenings, driving market growth.
Secondly, the increasing prevalence of Frasier syndrome has also contributed to market expansion. The need for effective renal replacement therapies and long-term management strategies has created a demand for innovative treatment options.
However, the market for Frasier syndrome faces certain restraints as well. Limited awareness among healthcare professionals and the general public about this rare disorder can lead to underdiagnosis and delayed treatment. Moreover, the high cost of genetic testing and specialized treatments poses a challenge for patients and their families.
Despite these challenges, the market for Frasier syndrome presents several opportunities. The development of targeted therapies and personalized medicine approaches holds promise for improved outcomes in patients with Frasier syndrome. Furthermore, collaborations between research institutions, pharmaceutical companies, and advocacy groups can help drive research on better diagnostic tools and treatment modalities.
Frasier Syndrome Market Segmentation: